๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nanjing
Clinical trial register · China

Clinical Trials in Nanjing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University201 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School89 Nanjing First Hospital, Nanjing Medical University68 The Second Hospital of Nanjing Medical University32 Nanjing Medical University30
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Nanjing

1193 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT04442022Relapsed/Refractory Diffuse Large B-cell Lymphoma
Karyopharm Therapeutics Inc
Phase 2/3
501
Nanjing, Suzhou, Huangpu, Xuhui, Chengdu, Hangzhou
2020-09-03
Active, closed
A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies
NCT04547049Leukemia, MDS
First Affiliated Hospital of Zhejiang University
Phase 3
232
Changsha, Chongqing, Hangzhou, Nanjing, Ningbo, Suzhou
2020-09-01
Recruiting
MR Microstructural Imaging for Prostate Cancer Diagnosis
NCT07249281Prostate Cancer, Diffusion MRI
First Affiliated Hospital of Zhejiang University
Observational
2,000
Beijing, Zhengzhou, Nanjing, Dalian, Hangzhou
2020-09-01
Recruiting
Establish Diagnostic and Prognostic Models for Preclinical AD Patients Based on Multimodal MRI, Behavioral, Genetic, and Plasma Biomarkers
NCT06561906Alzheimer Disease, Late Onset, Mild Cognitive Impairment, Subjective Cognitive Decline
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
1,000
Nanjing
2020-09-01
Recruiting
Screening of Susceptibility Genes for APAP Induced Drug Induced LIver Injury in ChiNese Population: a Case-control Study
NCT04964310Acetaminophen, Drug-Induced Liver Injury, Pharmacogenetics, China
The First Affiliated Hospital with Nanjing Medical University
Observational
339
Nanjing
2020-08-31
Recruiting
Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)
NCT06524427Non Small Cell Lung Cancer
Sun Yat-sen University
Not applicable
1,124
Chongqing, Lanzhou, Guangzhou, Shenzhen, Guilin, Zhengzhou, Wuhan, Nanjing
2020-08-25
Active, closed
Safety and Effectiveness of ENTERPRISE 2 Device in the Endovascular Treatment of Intracranial Aneurysms
NCT04289480Intracranial Aneurysm
Medos International SARL
Observational
164
Beijing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Nanchang, Shenyang, Shanghai
2020-07-30
Active, closed
Linerixibat Long-term Safety, and Tolerability Study
NCT04167358Cholestasis
GlaxoSmithKline
Phase 3
242
Beijing, Changchun, Chongqing, Guangzhou, Nanchang, Nanjing, Shanghai, Tianjin
2020-07-14
Recruiting
A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
NCT04316364Non-Small-Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
537
Beijing, Guangzhou, Zhengzhou, Nanjing, Shanghai, Chengdu, Hangzhou
2020-07-14
Active, closed
Phase III Study of Toripalimab๏ผˆJS001๏ผ‰ Combined With Lenvatinib for Advanced HCC
NCT04523493Advanced Hepatocellular Carcinoma (HCC)
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
530
Nanjing
2020-06-29
Recruiting
Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement
NCT04432714DLBCL, Untreated, MYC Gene Rearrangement
The First Affiliated Hospital with Nanjing Medical University
Phase 1/2
81
Nanjing
2020-06-09
Recruiting
Circulating Non-coding RNA in Acute Ischemic Stroke With Endovascular Treatment (EVTRNA)
NCT04230785Stroke, Acute, Stroke, Ischemic, Endovascular Treatment
Nanjing First Hospital, Nanjing Medical University
Observational
300
Nanjing
2020-03-15
Recruiting
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT04221542Prostate Cancer
Amgen
Phase 1
479
Beijing, Guangzhou, Nanchang, Shanghai, Hangzhou, Nanjing, Wenzhou
2020-03-04
Recruiting
Drug-coating Balloon Treatment in Coronary Artery Disease
NCT04255563Coronary Artery Disease
Nanjing First Hospital, Nanjing Medical University
Observational
3,000
Nanjing
2020-02-25
Not yet open
Choroidal Change on OCTA in Eyes With High Myopia
NCT04255524Myopia, Progressive, Choroid Disease
The First Affiliated Hospital with Nanjing Medical University
Not applicable
200
Nanjing
2020-02-01
Recruiting
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
NCT05406999Neoadjuvant Therapy, High Risk Prostate Cancer, Locally Advanced Prostate Cancer, Intense Endocrine Therapy
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
900
Nanjing
2020-02-01
Recruiting
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
NCT04192344Neoplasms, Tenosynovial Giant Cell Tumor
Abbisko Therapeutics Co, Ltd
Phase 1
276
Beijing, Guangdong, Shijiazhuang, Zhengzhou, Nanjing, Shenyang, Shanghai, Xian
2020-01-20
Active, closed
A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib
NCT04170283B-cell Malignancies
BeOne Medicines
Phase 3
955
Beijing, Fuzhou, Quanzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing
2020-01-16
Recruiting
Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)
NCT04519905Esophageal Squamous Cell Carcinoma, Chemoradiotherapy, Survival
Fudan University
Not applicable
320
Nanjing, Shanghai
2020-01-06
Active, closed
JiAngSu Maternal and INfant HEalth Database
NCT06641479Pregnant Women, Children
Yang Zhao
Observational
1,570,360
Nanjing
2020-01-01
Recruiting
Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa
NCT06926192Hidradenitis Suppurativa (HS), Hidradenitis Suppurativa (Acne Inversa), Secukinumab
Peking Union Medical College
Observational
100
Nanjing
2020-01-01
Active, closed
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
NCT04165317Non-muscle Invasive Bladder Cancer
Pfizer
Phase 3
1,068
Hefei, Beijing, Fuzhou, Wuhan, Changsha, Nanjing, Nantong, Suzhou
2019-12-30
Recruiting
CAES for Internal Hemorrhoids and Rectal Prolapse
NCT04169152Internal Hemorrhoid, Rectal Prolapse
Faming Zhang
Observational
10,000
Nanjing
2019-12-30
Recruiting
Circulating Non-coding RNA in Acute Ischemic Stroke (AISRNA)
NCT04175691Acute Stroke, Ischemic Stroke
Nanjing First Hospital, Nanjing Medical University
Observational
500
Nanjing
2019-11-24
Active, closed
The PREDICT Study: Prospective Early Detection In a Population at High-risk for Common Malignant Tumor
NCT04405557Early Detection of Cancer
Geneplus-Beijing Co. Ltd.
Observational
757
Beijing, Shenzhen, Zhengzhou, Changsha, Nanjing, Changchun, Jinzhou, Chengdu
2019-11-12
Active, closed
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
NCT03975647HER2-positive Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
466
Guangzhou, Zhanjiang, Zhengzhou, Changsha, Wuhan, Nanjing, Xuzhou, Nanchang
2019-10-02
Recruiting
Chemoradiotherapy in Unresectable Esophageal Cancer
NCT04278287Esophageal Cancer, Chemoradiotherapy, Albumin-bound Paxlitaxel, Unresectable Malignant Neoplasm
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2
105
Anyang, Changsha, Nanjing, Beijing
2019-10-01
Active, closed
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
NCT06239155Advanced Solid Tumors, Hepatocellular Carcinoma
Ascentawits Pharmaceuticals, Ltd
Phase 1/2
51
Guangzhou, Zhengzhou, Nanjing, Shenyang, Shanghai, Hangzhou
2019-09-03
Recruiting
OR6A2 on Monocytes and Cardiovascular Outcomes in Myocardial Ischemia-Reperfusion Injury
NCT07100457Myocardial Ischemia-Reperfusion Injury
Southeast University, China
Observational
200
Nanjing
2019-09-01
Active, closed
Predictors and Clinical Outcomes of Patients With Coronary Heart Disease Co-morbid Depression Post Percutaneous Coronary Intervention
NCT03852082Coronary Heart Disease, Percutaneous Coronary Intervention, Depression
Nanjing First Hospital, Nanjing Medical University
Observational
2,600
Nanjing
2019-08-28
Active, closed
1-month vs 12-month DAPT for ACS Patients Who Underwent PCI Stratified by IVUS: IVUS-ACS and ULTIMATE-DAPT Trials
NCT03971500Coronary Artery Disease
Nanjing First Hospital, Nanjing Medical University
Not applicable
3,710
Nanjing
2019-08-20
Active, closed
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia
NCT04119050Warm Autoimmune Hemolytic Anemia
Janssen Research & Development, LLC
Phase 2/3
118
Beijing, Changchun, Chengdu, Guangzhou, Haikou, Hangzhou, Lanzhou, Nanjing
2019-08-15
Recruiting
Pan Tumor Rollover Study
NCT03899155Cancer
Bristol-Myers Squibb
Phase 2
1,500
Hefei, Beijing, Guangzhou, Harbin, Changsha, Nanjing, Changchun, Xi'an
2019-08-09
Active, closed
ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC
NCT04143607Locally Advanced or Metastatic NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Phase 3
337
Beijing, Nanjing
2019-07-23
Recruiting
Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients
NCT03987308Type 2 Diabetic Patients, T2DM (Type 2 Diabetes Mellitus), T2DM
Beijing Hospital
Not applicable
115
Beijing, Guangzhou, Harbin, Nanjing, Xuzhou, Changchun, Xi'an, Luzhou
2019-07-02
Active, closed
Bronchial Ablation for Treatment of Asthma (BATA) Trial
NCT03765307Asthma
SyMap Medical (Suzhou), Ltd.
Not applicable
160
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Qiqihar, Nanjing, Suzhou, Xuzhou
2019-06-18
Recruiting
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
NCT03773965Juvenile Idiopathic Arthritis
Eli Lilly and Company
Phase 3
190
Beijing, Chongqing, Nanjing, Suzhou
2019-04-05
Active, closed
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
NCT03887455Early Alzheimer's Disease
Eisai Inc.
Phase 3
1,906
Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Changsha, Baotou, Nanjing, Changchun
2019-03-27
Active, closed
Intra-operative Pancreatoscopy in Patients With IPMN
NCT03729453Intraductal Papillary Mucinous Neoplasm
Boston Scientific Corporation
Observational
100
Nanjing
2019-03-20
Active, closed
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
NCT03748641Castration-Resistant Prostatic Cancer
Janssen Research & Development, LLC
Phase 3
765
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Ningbo, Shanghai
2019-01-25
Active, closed
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
NCT03734029Breast Cancer
Daiichi Sankyo
Phase 3
557
Hefei, Beijing, Fuzhou, Guangzhou, Harbin, Wuhan, Nanjing, Changchun
2018-12-27
Active, closed
IVUS-guided DK Crush Stenting Technique for Patients With Complex Bifurcation Lesions
NCT03770650Coronary Artery Disease
Nanjing First Hospital, Nanjing Medical University
Not applicable
556
Nanjing
2018-12-26
Active, closed
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer
NCT03701334Early Breast Cancer
Novartis Pharmaceuticals
Phase 3
5,101
Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Nanjing, Suzhou, Changchun
2018-12-07
Active, closed
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC
NCT03562637Triple Negative Breast Cancer
OBI Pharma, Inc
Phase 3
575
Beijing, Guangzhou, Nanning, Harbin, Wuhan, Changsha, Nanjing, Changchun
2018-12-05
Active, closed
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
NCT03539744Multiple Myeloma
AbbVie
Phase 3
265
Beijing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang, Shenyang
2018-10-22
Recruiting
Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis
NCT04592640Chronic Kidney Diseases, Calciphylaxis, Calcific Uremic Arteriolopathy, Treatment
The First Affiliated Hospital with Nanjing Medical University
Phase EARLY_PHASE1
9
Nanjing
2018-09-17
Active, closed
A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer
NCT03523442Prostatic Neoplasms
Janssen Research & Development, LLC
Phase 1
19
Beijing, Nanjing, Shanghai
2018-08-31
Active, closed
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
NCT03398135Ulcerative Colitis (UC)
AbbVie
Phase 3
1,242
Hefei, Beijing, Guangzhou, Shijiazhuang, Wuhan, Changsha, Huaian, Nanjing
2018-08-28
Active, closed
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.
Phase 3
565
Haerbin, Nanjing, Hangzhou, Beijing, Hefei, Xiamen, Zhengzhou
2018-06-21
Active, closed
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
NCT03755791Hepatocellular Carcinoma
Exelixis
Phase 3
837
Hefei, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing
2018-06-10
Recruiting
Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC
NCT06876753Hepatocellular Carcinoma (HCC)
Zhongda Hospital
Observational
300
Nanjing
2018-06-01
Recruiting
Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease
NCT05461820Graves Disease, Relapse, Treatment, Drug Withdrawal
The First Affiliated Hospital with Nanjing Medical University
Phase 4
240
Nanjing
2018-05-01
Recruiting
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
NCT03460977Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL)
Pfizer
Phase 1
453
Guangzhou, Changsha, Nanjing, Chengdu, Wenzhou
2018-04-17
Active, closed
Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC
NCT03478488Biliary Tract Neoplasms
3D Medicines (Sichuan) Co., Ltd.
Phase 3
480
Nanjing
2018-04-16
Active, closed
CCCG-HD-2018 for Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma
NCT04726501Hodgkin Lymphoma
Children's Cancer Group, China
Phase 4
200
Chengdu, Nanjing, Shanghai
2018-04-01
Active, closed
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
NCT03390504Urothelial Cancer
Janssen Research & Development, LLC
Phase 3
629
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing
2018-03-23
Active, closed
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
NCT03345823Crohn's Disease
AbbVie
Phase 3
747
Beijing, Xiamen, Guangzhou, Wuhan, Changsha, Nanjing, Nanchang, Changchun
2018-03-21
Recruiting
Fecal Microbiota Transplantation for Radiation Enteritis
NCT03516461Radiation Enteritis
The Second Hospital of Nanjing Medical University
Not applicable
70
Nanjing
2018-01-07
Recruiting
Microbiota Transplantation in Solid Organ Transplantation
NCT06730451Solid Organ Transplant Complications
The Second Hospital of Nanjing Medical University
Observational
50
Nanjing
2018-01-01
Active, closed
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
NCT03395197mCRPC
Pfizer
Phase 3
1,054
Hefei, Beijing, Fuzhou, Xiamen, Wuhan, Lianyungang, Nanjing, Nantong
2017-12-18
Active, closed
Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy
NCT03315364Recurrent or Metastatic Breast Cancer
Daehwa Pharmaceutical Co., Ltd.
Phase 2/3
549
Hefei, Beijing, Guangzhou, Haikou, Harbin, Zhengzhou, Nanjing, Changchun
2017-12-18
Active, closed
A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
NCT03319667Plasma Cell Myeloma
Sanofi
Phase 3
475
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Shenyang
2017-12-07
Active, closed
BioGlue as an Adjunct for Structural Repair and Hemostasis in Chinese Acute Type A Aortic Dissections Patients
NCT03369977Type A Aortic Dissection
CryoLife, Inc.
Not applicable
202
Beijing, Nanjing, Shanghai, Wuhan, Zhengzhou
2017-11-01
Active, closed
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT03178552Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2/3
1,000
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing
2017-09-22
Active, closed
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
NCT03155997Breast Cancer
Eli Lilly and Company
Phase 3
5,637
Beijing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing, Jinan
2017-07-12
Active, closed
A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short Stature
NCT03255694Dwarfism
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 2
360
Beijing, Wuhan, Changsha, Naning, Nanjing, Wuxi, Nanchang, Changchun
2017-05-12
Active, closed
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
NCT03036098Urothelial Cancer
Bristol-Myers Squibb
Phase 3
1,314
Beijing, Chongqing, Guiyang, Harbin, Wuhan, Nanjing, Changchun, Taiyuan
2017-03-24
By invitation
Development of Obesity and Bariatric Surgery
NCT03296605Obesity
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
150
Nanjing
2017-03-01
Active, closed
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naรฏve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
NCT02993523Acute Myeloid Leukemia (AML)
AbbVie
Phase 3
443
Fuzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Changchun, Shanghai
2017-02-02
Active, closed
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
NCT02960022Prostate Cancer
Astellas Pharma Global Development, Inc.
Phase 2
900
Hubei, Hunan, Nanjing
2016-12-22
Active, closed
Impact of BMI on CDK4/6 Inhibitors Efficacy and Safety in Advanced Breast Cancer
NCT06926088Advanced Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Observational
500
Nanjing
2016-12
Recruiting
China Diabetes Cognitive Dysfunction Early Diagnosis and Intervention Study (China-DECODE Study)
NCT06650969Type 2 Diabetes, Subjective Cognitive Decline, Mild Cognitive Impairment, Dementia
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
10,000
Nanjing
2016-10-01
Active, closed
Sympathetic Mapping/ Ablation of Renal Nerves Trial
NCT02761811Hypertension
SyMap Medical (Suzhou), Ltd.
Not applicable
220
Beijing, Chongqing, Shenzhen, Shijiazhuang, Daqing, Wuhan, Nanjing, Xuzhou
2016-06-30
Active, closed
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
NCT02767804Non-small Cell Lung Cancer
Xcovery Holdings, Inc.
Phase 3
290
Hefei, Beijing, Fuzhou, Guangzhou, Shijiazhuang, Changsha, Wuhan, Nanjing
2016-06
Recruiting
Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients
NCT06350825Metastatic Prostate Cancer, Therapy, Directly Observed
The First Affiliated Hospital with Nanjing Medical University
Phase 3
200
Nanjing
2016-01-01
Recruiting
Research on Optimal Diagnosis and Treatment of Cardiorenal Syndrome
NCT05397392Heart Failure, Kidney Diseases, Kidney Injury, Heart Valve Diseases
Nanjing First Hospital, Nanjing Medical University
Observational
1,200
Nanjing
2016-01
Active, closed
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
NCT02489318Prostate Cancer
Aragon Pharmaceuticals, Inc.
Phase 3
1,052
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai
2015-11-27
Active, closed
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
NCT02531516Prostatic Neoplasms
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Ningbo
2015-11-19
Active, closed
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
NCT02516241Urothelial Cancer
AstraZeneca
Phase 3
1,126
Beijing, Changchun, Changsha, Chongqing, Hangzhou, Nanjing, Shanghai, Shenyang
2015-11-02
Active, closed
AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.
NCT02511106Stage IB-IIIA Non-small Cell Lung Carcinoma
AstraZeneca
Phase 3
682
Beijing, Changchun, Dalian, Guangzhou, Hangzhou, Kunming, Nanjing, Nanning
2015-10-21
Active, closed
A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
NCT02519348Hepatocellular Carcinoma
MedImmune LLC
Phase 2
433
Hangzhou, Nanjing, Shanghai
2015-10-19
Recruiting
Rescue Fecal Microbiota Transplantation for National Refractory Intestinal Infections
NCT03895593Intestinal Infection, Clostridioides Difficile Infection, Antibiotic-associated Diarrhea
The Second Hospital of Nanjing Medical University
Observational
100
Nanjing
2015-09-25
Active, closed
A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
NCT02320435Solid Tumors
Hoffmann-La Roche
Phase 3
154
Beijing, Changchun, Chengdu, Hangzhou, Harbin, Nanjing, Shanghai, Shenyang
2015-02-02
Active, closed
Effects of Extracorporeal Treatment in Patients With Acute Poisoning
NCT06798129Poisoning, Extracorporeal Treatment
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
5,269
Nanjing
2015-01-01
Active, closed
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
NCT02032823Breast Cancer
AstraZeneca
Phase 3
1,837
Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Jinan, Nanjing
2014-04-22
Recruiting
A Clinical Study of Paclitaxel Cationic Liposomes for the Treatment of Patients With Advanced Solid Tumors
NCT06632574Advanced Solid Tumor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1
60
Nanjing
2014-03-19
By invitation
Autologous Stem Cell Transplantation for Patients With AL Amyloidosis
NCT04210791AL Amyloidosis, Plasma Cell Dyscrasia
Nanjing University School of Medicine
Observational
500
Nanjing
2010-07-01
Active, closed
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
NCT00781612Neoplasm Metastasis
Genentech, Inc.
Phase 2
378
Beijing, Changchun, Guangzhou, Hangzhou, Harbin, Nanjing, Shanghai
2008-10-16
Recruiting
"Real-life" Cohort Study on Patients With Chronic HBV Infection in Jiangsu
NCT03097952Hepatitis B๏ผŒ Chronic
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
20,000
Changzhou, Huai'an, Nanjing, Suqian, Suzhou
2008-01
Recruiting
Nutrition Support on Outcomes and Cost-effectiveness for Patients at Risk
NCT00289380Malnutrition, Nutritional Risk
Peking Union Medical College
Observational
2,000
Beijing, Chongqing, Guangzhou, Nanning, Shijiazhuang, Tianjin, Wuhan, Nanjing
2005-01
Recruiting
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
NCT04821778Esophagus Cancer, Esophagogastric Junction Cancer, Chemoradiation, Targeted Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
2,000
Anyang, Changsha, Nanjing, Beijing
2002-01-01
Recruiting
Fabry Disease Registry & Pregnancy Sub-registry
NCT00196742Fabry Disease
Genzyme, a Sanofi Company
Observational
9,000
Beijing, Hangzhou, Jinan, Nanjing, Shanghai
2001-07-31
Recruiting
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
NCT00358943Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease
Genzyme, a Sanofi Company
Observational
12,000
Beijing, Guangzhou, Hangzhou, Nanjing, Shanghai
1991-04-01
Rows per page Showing 1101–1193 of 1193
Previous 10 11 12
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/nanjing?page=12

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,193 of those studies with a site in Nanjing.

How many clinical trials are recruiting in Nanjing?

713 of the 1,193 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 232 have not yet opened recruitment, 216 are active but closed to new participants, and 32 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.